source
- Deaths of two Chinese children receiving CRISPR therapy spark safety debateTwo children in China died after receiving experimental CRISPR-based gene therapies, according to a recent report. The fatalities have unsettled researchers in the United States who are developing…
- Novartis signs up to $3.2 billion deal with Korea's Alteogen for subcutaneous drug delivery technologyNovartis has entered an option and license agreement with Korean biotech Alteogen to use its ALT-B4 subcutaneous delivery platform, a partnership that could be worth up to $3.2 billion if all optio…